All articles by Sdebbarma Sdebbarma
Sdebbarma Sdebbarma
Denali makes $275m funding agreement with Royalty Pharma
Completion of the agreement remains contingent on several closing conditions.
Pliant Therapeutics reports interim PLN-101095 Phase I trial data
The drug was well tolerated throughout all doses, with two discontinuations due to adverse events.
Takeda and Innovent fulfil close conditions for ADC and IO therapies
The companies will jointly develop IBI363 on a global scale and co-commercialise the therapy in the US.
Debiopharm randomises first patient in Phase III acromegaly trial
Debio 4126 is intended for intramuscular injection every three months.
Formosa and Rxilient sign licensing agreement for APP13007
The agreement includes upfront payments, sales and regulatory milestones.
FDA approves Eli Lilly’s Jaypirca in relapsed or refractory CLL/SLL
The decision broadens Jaypirca’s label and converts the December 2023 accelerated approval to a traditional approval status.
Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours
The RNDO-564 trial is designed to address limitations of Nectin-4–targeting ADCs.
FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS
The antibody is designed to target toxic forms of TDP-43 selectively, aiming to restore normal nuclear function.
PolarityBio concludes SkinTE’s Phase III trial for diabetic foot ulcers
Subjects were randomised one-to-one to SkinTE plus SOC or SOC alone, followed for 24 weeks.
AGC Biologics to expand cell line development with ATUM partnership
ATUM’s Leap-In platform enables AGC Biologics to offer various cell line development solutions for customers.